Cresset Asset Management LLC Purchases New Stake in Hims & Hers Health, Inc. $HIMS

Key Points

• Cresset Asset Management LLC has acquired a new stake in Hims & Hers Health, Inc. worth approximately $291,000, purchasing 9,858 shares during the first quarter.
• Recent analysts' ratings for Hims & Hers Health show a consensus of two Buy ratings, eight Hold ratings, and three Sell ratings, with an average target price of $38.92.
• CEO Andrew Dudum sold 660,000 shares of Hims & Hers for over $33 million, reducing his ownership by nearly 23% after insider sales totaled approximately $71.7 million in recent months.

Cresset Asset Management LLC purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 9,858 shares of the company's stock, valued at approximately $291,000.

A number of other institutional investors have also recently modified their holdings of the business. Allworth Financial LP boosted its stake in shares of Hims & Hers Health by 20.0% in the first quarter. Allworth Financial LP now owns 2,006 shares of the company's stock valued at $56,000 after buying an additional 334 shares in the last quarter. Signaturefd LLC boosted its stake in shares of Hims & Hers Health by 17.7% in the first quarter. Signaturefd LLC now owns 2,586 shares of the company's stock valued at $76,000 after buying an additional 388 shares in the last quarter. Larson Financial Group LLC boosted its stake in shares of Hims & Hers Health by 47.7% in the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock valued at $42,000 after buying an additional 458 shares in the last quarter. Cim LLC boosted its stake in shares of Hims & Hers Health by 1.0% in the fourth quarter. Cim LLC now owns 71,869 shares of the company's stock valued at $1,738,000 after buying an additional 694 shares in the last quarter. Finally, LPL Financial LLC boosted its stake in shares of Hims & Hers Health by 0.8% in the first quarter. LPL Financial LLC now owns 98,701 shares of the company's stock valued at $2,917,000 after buying an additional 743 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on HIMS shares. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Zacks Research cut Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and set a $40.00 price objective on shares of Hims & Hers Health in a report on Wednesday, June 11th. Two research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Reduce" and an average target price of $38.92.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 660,000 shares of the company's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total value of $33,382,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,214,769 shares in the company, valued at approximately $112,023,016.02. This represents a 22.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Michael Chi sold 17,102 shares of the company's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total value of $1,021,844.50. Following the completion of the transaction, the insider owned 278,654 shares of the company's stock, valued at $16,649,576.50. The trade was a 5.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,392,857 shares of company stock valued at $71,746,999. 17.71% of the stock is owned by insiders.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $43.03 on Tuesday. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98. The stock has a market cap of $9.73 billion, a price-to-earnings ratio of 53.79, a price-to-earnings-growth ratio of 3.01 and a beta of 2.08. The business has a fifty day moving average of $51.37 and a 200-day moving average of $45.85. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same period last year, the firm earned $0.06 earnings per share. The business's revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.